DE60218193D1 - Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia - Google Patents

Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia

Info

Publication number
DE60218193D1
DE60218193D1 DE60218193T DE60218193T DE60218193D1 DE 60218193 D1 DE60218193 D1 DE 60218193D1 DE 60218193 T DE60218193 T DE 60218193T DE 60218193 T DE60218193 T DE 60218193T DE 60218193 D1 DE60218193 D1 DE 60218193D1
Authority
DE
Germany
Prior art keywords
oxo
dyskinesia
medicament
preparation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60218193T
Other languages
English (en)
Other versions
DE60218193T2 (de
Inventor
Renee Grimee
Henrik Klitgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of DE60218193D1 publication Critical patent/DE60218193D1/de
Publication of DE60218193T2 publication Critical patent/DE60218193T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60218193T 2001-10-08 2002-10-07 Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia Expired - Lifetime DE60218193T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01123976 2001-10-08
EP01123976 2001-10-08
PCT/EP2002/011203 WO2003030899A2 (en) 2001-10-08 2002-10-07 Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders

Publications (2)

Publication Number Publication Date
DE60218193D1 true DE60218193D1 (de) 2007-03-29
DE60218193T2 DE60218193T2 (de) 2007-11-22

Family

ID=8178883

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60218193T Expired - Lifetime DE60218193T2 (de) 2001-10-08 2002-10-07 Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia

Country Status (12)

Country Link
US (2) US20040242671A1 (de)
EP (1) EP1435943B1 (de)
JP (1) JP4351909B2 (de)
AT (1) ATE353645T1 (de)
AU (1) AU2002340971B2 (de)
CA (1) CA2461961A1 (de)
DE (1) DE60218193T2 (de)
ES (1) ES2281545T3 (de)
HU (1) HUP0401667A2 (de)
MX (1) MXPA04002714A (de)
PL (1) PL370529A1 (de)
WO (1) WO2003030899A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071449A2 (en) 2003-02-12 2004-08-26 Bristol-Myers Squibb Company Lactams as modulators of chemokine receptor activity
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20110212944A1 (en) * 2008-07-01 2011-09-01 Julie Liu 2-oxo-1-pyrrolidine derivatives
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2012027825A1 (en) * 2010-08-31 2012-03-08 Mcmaster University Method of treating dopamine-related neuropsychiatric disorders
DK3077374T3 (da) 2013-12-03 2020-05-04 Fmc Corp Pyrrolidinoner som herbicider
US11589583B2 (en) 2013-12-03 2023-02-28 Fmc Corporation Pyrrolidinones herbicides
MX2016017251A (es) 2014-07-02 2017-04-27 Du Pont Herbicidas de piperidinona.
MX2017007087A (es) 2014-12-08 2017-09-05 Du Pont 3-oxo-3-(arilamino)propanoatos, proceso para su preparacion y su uso en la preparacion de pirrolidinonas.
JP6956637B2 (ja) 2015-04-10 2021-11-02 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤としての置換環状アミド
EP3288928B1 (de) 2015-04-27 2021-10-13 FMC Corporation Butyrolactone als herbizide
EP3650430A1 (de) 2015-05-12 2020-05-13 FMC Corporation Zwischenprodukte und prozessen für die synthese von herbiziden
WO2016196019A1 (en) 2015-05-29 2016-12-08 E I Du Pont De Nemours And Company Substituted cyclic amides as herbicides
JP6949730B2 (ja) 2015-06-02 2021-10-13 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 置換環状アミドおよび除草剤としてのそれらの使用
JP6937290B2 (ja) 2015-07-31 2021-09-22 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 除草剤として有用な環状ｎ−カルボキサミド化合物
AU2017378640B2 (en) 2016-12-21 2022-03-03 Fmc Corporation Nitrone herbicides
UA126576C2 (uk) 2017-03-21 2022-11-02 ЕфЕмСі КОРПОРЕЙШН Гербіцидна суміш, композиція та спосіб
WO2018175226A1 (en) 2017-03-21 2018-09-27 Fmc Corporation Pyrrolidinones and a process to prepare them
AR111839A1 (es) 2017-05-30 2019-08-21 Fmc Corp Lactamas 3-sustituidas herbicidas
AR111967A1 (es) 2017-05-30 2019-09-04 Fmc Corp Amidas herbicidas
GB201901559D0 (en) 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB8412357D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
HUP0204023A3 (en) * 1999-12-01 2005-03-29 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders

Also Published As

Publication number Publication date
DE60218193T2 (de) 2007-11-22
ES2281545T3 (es) 2007-10-01
WO2003030899A2 (en) 2003-04-17
MXPA04002714A (es) 2004-07-05
AU2002340971B2 (en) 2007-04-26
HUP0401667A2 (hu) 2004-12-28
US20080167366A1 (en) 2008-07-10
US20040242671A1 (en) 2004-12-02
EP1435943A2 (de) 2004-07-14
WO2003030899A3 (en) 2004-01-08
ATE353645T1 (de) 2007-03-15
CA2461961A1 (en) 2003-04-17
PL370529A1 (en) 2005-05-30
JP4351909B2 (ja) 2009-10-28
JP2005504834A (ja) 2005-02-17
EP1435943B1 (de) 2007-02-14

Similar Documents

Publication Publication Date Title
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
SG169233A1 (en) Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
DE60320579D1 (de) Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
WO2005062992A3 (en) Substituted melatonin derivatives, process for their preparation, and methods of use
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
EA200970021A1 (ru) Комбинированные препараты, содержащие slv308 и l-dopa
DE60222662D1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung
DE602006002126D1 (de) Verwendung von zinkgluconat zur behandlung von hydradenitis suppurativa
DE69923698D1 (de) Verwendung von 3-(1h-imidazol-4-ylmethyl)-indan-5-ol zur herstellung eines medikamentes zur intraspinalen, intrathekalen und epiduralen anwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UCB PHARMA, S.A., BRUXELLES, BE